Recombinant tumor necrosis factor: its effect and its sy variety of normal and transformed human cell lines

European Journal of Cancer & Clinical Oncology 22, 419-426

DOI: 10.1016/0277-5379(86)90107-0

Citation Report

#	Article	IF	CITATIONS
1	In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN- \hat{l}^3 , on a syngeneic murine melanoma. International Journal of Cancer, 1986, 38, 763-769.	2.3	170
2	Treatment of Murine Interferon- $\hat{l}\pm\hat{l}^2$ -Sensitive and -Resistant Friend Leukemia Cells with Tumor Necrosis Factor in Combination with Murine Interferon- $\hat{l}\pm\hat{l}^2$ or $-\hat{l}^3$. Journal of Interferon Research, 1986, 6, 633-638.	1.2	2
3	Tumor Necrosis Factor: A Potential Antitumor Agent?. Journal of Interferon Research, 1987, 7, 627-634.	1.2	7
5	Tumour necrosis factor in man: Clinical and biological observations. British Journal of Cancer, 1987, 56, 803-808.	2.9	204
6	Induction and regulation of mRNA encoding 26-kDa protein in human cell lines treated with recombinant human tumor necrosis factor Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 4557-4561.	3.3	84
7	The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 4273-4277.	3.3	281
8	The effect of recombinant human tumour necrosis factor on growth and macromolecular synthesis of human epithelial cells. Experimental Cell Research, 1987, 170, 428-438.	1.2	26
9	In vitro effects of thymosin and lithium on lymphoproliferative responses of normal donors and HIV seropositive male homosexuals with AIDS-related complex. Clinical Immunology and Immunopathology, 1987, 44, 51-62.	2.1	23
10	Metabolism of protein anticancer agents. , 1987, 34, 1-49.		54
11	Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. International Journal of Cancer, 1987, 39, 266-273.	2.3	77
12	Characterization of 3ll-tumor variants generated byin vitro macrophage-mediated selection. International Journal of Cancer, 1987, 39, 343-352.	2.3	29
13	Anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) on colon cancer in rats is promoted by recombinant rat interferon gamma; toxicity is reduced by indomethacin. International Journal of Cancer, 1987, 40, 550-553.	2.3	31
14	DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon- \hat{l}^3 . European Journal of Immunology, 1987, 17, 689-693.	1.6	136
15	Recombinant tumor necrosis factor can induce interleukin 2 receptor expression and cytolytic activity in a rat $ ilde{A}-$ mouse T cell hybrid. European Journal of Immunology, 1987, 17, 1835-1838.	1.6	42
16	Gene cloning and structure - function relationship of cytokines such as TNF and interleukins. Immunology Letters, 1987, 16, 219-226.	1.1	8
17	Protection from tumor necrosis factor cytotoxicity by protease inhibitors. Cellular Immunology, 1987, 107, 317-325.	1.4	72
18	Monocyte-Derived Influence on Growth of Normal Human Fibroblasts Scandinavian Journal of Immunology, 1987, 26, 175-185.	1.3	7
19	Recombinant human tumor necrosis factor- $\hat{l}\pm$: Thrombus formation is a cause of anti-tumor activity. International Journal of Cancer, 1988, 41, 243-247.	2.3	108

#	Article	IF	CITATIONS
20	Tumor-selective cytotoxic effects of murine tumor necrosis factor (TNF) and interferon-gamma (EN-gamma) in organ culture of B16 melanoma cells and heart tissue. International Journal of Cancer, 1988, 42, 470-473.	2.3	18
21	Tumor necrosis factor α induces early morphologic and metabolic alterations in friend leukemia cell tumors and fibrosarcomas in mice. International Journal of Cancer, 1988, 42, 582-591.	2.3	25
22	Effects of recombinant human tumor necrosis factor- \hat{l}_{\pm} on the surface phenotype and the growth of human malignant glioma cell lines. International Journal of Cancer, 1988, 42, 780-786.	2.3	35
23	Tumor necrosis factor stimulates proliferation of human osteosarcoma cells and accumulation ofc-myc messenger RNA. Journal of Cellular Physiology, 1988, 134, 479-484.	2.0	37
24	Mitogenic action of tumor necrosis factor in human fibroblasts: Interaction with epidermal growth factor and platelet-derived growth factor. Journal of Cellular Physiology, 1988, 135, 23-31.	2.0	52
25	An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2c, interferon gamma and tumour necrosis factor. Acta Neurochirurgica, 1988, 91, 60-66.	0.9	6
26	Resistance of tumor cells to tumor necrosis factor. Journal of Clinical Immunology, 1988, 8, 333-341.	2.0	44
27	Natural cytotoxicity of rat hepatic natural killer cells and macrophages against a syngeneic colon adenocarcinoma. Cancer Immunology, Immunotherapy, 1988, 27, 137-41.	2.0	55
28	In vitro antiproliferative efficacy of Interferon-alpha,-gamma and Tumor Necrosis Factor on two human renal tumor xenografts. Urological Research, 1988, 16, 309-314.	1.5	11
29	Effect of alpha- and gamma-Interferon and tumor necrosis factor on colony formation of two human renal tumor xenografts in vitro. Journal of Surgical Oncology, 1988, 4, 195-198.	1.4	8
30	Up-regulation of the Expression of Secretory Component and HLA Molecules in a Human Colonic Cell Line by Tumour Necrosis Factor-alpha and Gamma Interferon. Scandinavian Journal of Immunology, 1988, 28, 351-357.	1.3	121
31	Perforin-Dependent and -Independent Pathways of Cytotoxicity Mediated by Lymphocytes. Immunological Reviews, 1988, 103, 161-202.	2.8	83
32	Inhibitory Effect of Gamma Interferon on Cultured Human Keratinocyte Thrombospondin Production, Distribution, and Biologic Activities. Journal of Investigative Dermatology, 1988, 91, 213-218.	0.3	32
33	Dexamethasone inhibits the cytotoxic activity of tumor necrosis factor. Biochemical and Biophysical Research Communications, 1988, 153, 109-115.	1.0	23
34	The multiple roles of tumour necrosis factor. Annales De L'Institut Pasteur Immunologie, 1988, 139, 281-288.	0.9	3
35	Cachectin/TNF Production in Experimental Burns and Pseudomonas Infection. Archives of Surgery, 1988, 123, 1383.	2.3	71
36	Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses Journal of Cell Biology, 1988, 107, 1269-1277.	2.3	435
37	Destruction of Rat Islet Cell Monolayers by Cytokines: Synergistic Interactions of Interferon-Î ³ , Tumor Necrosis Factor, Lymphotoxin, and Interleukin 1. Diabetes, 1988, 37, 133-136.	0.3	295

#	Article	IF	CITATIONS
38	In vivo hematopoietic effects of tumor necrosis factor-alpha in normal and erythroleukemic mice: characterization and therapeutic applications. Blood, 1988, 72, 1875-1883.	0.6	47
39	Differential biologic effects resulting from bimodal binding of recombinant human tumor necrosis factor to myeloid leukemia cells. Blood, 1989, 73, 419-424.	0.6	23
40	Recombinant Human Tumor Necrosis Factor Alone and With Chemotherapeutic Agents. Archives of Surgery, 1989, 124, 107.	2.3	19
41	Effects of Interferon- \hat{I}^3 and Tumor Necrosis Factor- \hat{I}^\pm on Macrophage Enzyme Levels. Journal of Interferon Research, 1989, 9, 1-9.	1.2	9
42	Inhibitory Effects of Tumor Necrosis Factor- \hat{l}_{\pm} and Interferon- \hat{l}_{3} on Deoxyribonucleic Acid and Collagen Synthesis by Rat Osteosarcoma Cells (ROS 17/2.8). Endocrinology, 1989, 124, 339-345.	1.4	80
43	Tumor necrosis factor-mediated cytotoxicity by tumor-associated macrophages. Cellular Immunology, 1989, 123, 158-165.	1.4	12
44	Cytokines and pancreatic cancer the effect of rIFN- \hat{l}^3 , HuLelFN, rTNF- \hat{l}^{\pm} , and LAK-cells on pancreatic and other gastrointestinal tumors in vitro. International Journal of Gastrointestinal Cancer, 1989, 4, 207-219.	0.4	5
45	Cytokines and pancreatic cancer. International Journal of Gastrointestinal Cancer, 1989, 4, 303-319.	0.4	6
46	Expression of the genes of interferons and other cytokines in normal and diseased tissues of man. Experientia, 1989, 45, 526-535.	1.2	20
47	TNF-α mediated selection of macrophage-resistant gene-regulatory tumor variants. Clinical and Experimental Metastasis, 1989, 7, 493-506.	1.7	3
48	Effects of interferonâ€gamma and tumor necrosis factorâ€alpha on clonogenic growth of cell lines and primary cultures from human gliomas and brain metastases. Apmis, 1989, 97, 569-574.	0.9	15
49	Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines. International Journal of Cancer, 1989, 43, 526-530.	2.3	33
50	Increased peripheral blood leukocyte cytotoxic activity in cancer patients during the continuous intravenous administration of recombinant human tumor necrosis factor. Journal of Clinical Immunology, 1989, 9, 34-38.	2.0	6
51	Enhancement of Cytotoxicity of Cisplatinin vitroby Recombinant Human Tumor Necrosis Factor and/or Recombinant Human Interferon- \hat{l}_{\pm} , \hat{l}^2 and $-\hat{l}^3$. Japanese Journal of Cancer Research, 1989, 80, 904-909.	1.7	9
52	Effect of human recombinant tumour necrosis factor and rat gamma interferon on nitrosomethylurea-induced mammary tumours. British Journal of Cancer, 1989, 59, 206-209.	2.9	15
53	A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor Journal of Experimental Medicine, 1989, 169, 1747-1756.	4.2	1,445
54	Inhibition of tumor cell proliferation by a novel growth regulator from placenta: modulation of membrane phosphorylation and oncogene expression. Cancer Letters, 1989, 44, 227-231.	3.2	1
55	Assays for tumour necrosis factor and related cytokines. Journal of Immunological Methods, 1989, 116, 1-17.	0.6	208

#	Article	IF	Citations
56	Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor. FEBS Letters, 1989, 248, 169-174.	1.3	138
57	Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 9494-9498.	3.3	84
58	Divergent Effects of Interferons on the Growth of Human Benign Prostatic Hyperplasia Cells in Primary Culture. Journal of Urology, 1989, 141, 157-160.	0.2	20
59	Effect of Tumor Necrosis Factor and Interferon Gamma on Human Renal Carcinoma Cell Line Growth. Journal of Urology, 1989, 142, 875-878.	0.2	13
60	In Vitro and in Vivo Anti-Tumor Activity of Recombinant Mouse Tumor Necrosis Factor (TNF) in a Mouse Bladder Tumor (MBT-2). Journal of Urology, 1990, 144, 172-175.	0.2	20
61	Cytostatic and Cytotoxic Effects of Recombinant Tumor Necrosis Factor-α on Sensitive Human Melanoma Cells In Vitro May Result in Selection of Cells with Enhanced Markers of Malignancy. Journal of Investigative Dermatology, 1990, 95, S223-S230.	0.3	16
62	Long-term effect of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. International Journal of Gastrointestinal Cancer, 1990, 6, 109-118.	0.4	4
63	Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells. Cancer Chemotherapy and Pharmacology, 1990, 26, 1-8.	1.1	28
64	TNF: A brief review with emphasis on its antitumor activity. Biotherapy (Dordrecht, Netherlands), 1990, 2, 275-281.	0.7	13
65	Biological response modifiers in the management of patients with breast cancer. Breast Cancer Research and Treatment, 1990, 16, 67-87.	1.1	2
66	Common expression of a tumor necrosis factor resistance mechanism among gynecological malignancies. Cancer Immunology, Immunotherapy, 1990, 32, 131-136.	2.0	13
67	Structure, récepteurs et métabolisme de trois cytokines : interleukine-1, interleukine-6 et cachectine (tumor necrosis factor alpha). Nutrition Clinique Et Metabolisme, 1990, 4, 117-130.	0.2	1
68	Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Urological Research, 1990, 18, 245-250.	1.5	11
69	Influence of intravesical administration of tumor necrosis factor? and systemic?-interferon on murine bladder cancer: Lack of dose response. Urological Research, 1990, 18, 287-289.	1.5	6
70	Tumor necrosis factor-alpha inhibits cell proliferation and induces class II antigens and cell adhesion molecules in cultured normal human keratinocytes in vitro. Archives of Dermatological Research, 1990, 282, 238-245.	1.1	60
71	Synergistic induction of polypeptides by tumor necrosis factor and interferon-gamma in cells sensitive or resistant to tumor necrosis factor: Assessment by computer based analysis of two-dimensional gels using the PDQUEST system. Electrophoresis, 1990, 11, 232-241.	1.3	22
72	Effect of inflammatory cytokines on human endothelial cell proliferation. Journal of Cellular Physiology, 1990, 142, 488-495.	2.0	59
73	Glutamine or Fiber Supplementation of a Defined Formula Diet: Impact on Bacterial Translocation, Tissue Composition, and Response to Endotoxin. Journal of Parenteral and Enteral Nutrition, 1990, 14, 335-343.	1.3	86

#	ARTICLE	IF	Citations
74	Evidence for Two Classes of Cytokines That Stimulate Hepatic Lipogenesis: Relationships among Tumor Necrosis Factor, Interleukin-1 and Interferon-Alpha*. Endocrinology, 1990, 127, 46-54.	1.4	106
75	Tumour necrosis factor as an anticancer agent. European Journal of Cancer & Clinical Oncology, 1990, 26, 641-644.	0.9	46
76	Modulation by interleukin 1 and tumor necrosis factor $\hat{l}\pm$ of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochimica Et Biophysica Acta - Molecular Cell Research, 1990, 1052, 366-378.	1.9	221
77	Proliferative and antiproliferative effects of interferon-'Y and tumor necrosis factor-α. on cell lines derived from cervical and ovarian malignancies. American Journal of Obstetrics and Gynecology, 1990, 163, 1920-1924.	0.7	27
78	The efficacy of combined treatment with recombinant human tumor necrosis factor- \hat{l}_{\pm} and 5-fluorouracil is dependent on the development of capillaries in tumor. European Journal of Cancer & Clinical Oncology, 1990, 26, 93-99.	0.9	13
79	Effect of prostaglandin E in multiple experimental models. IV. Effect on resistance to endotoxin and tumor necrosis factor shock. Journal of Surgical Research, 1990, 49, 328-332.	0.8	20
80	Effects of murine recombinant interferon-gamma on rat liver fat storing cell proliferation, cluster formation and proteoglycan synthesis. Biochemical Pharmacology, 1990, 40, 1953-1962.	2.0	10
81	Influence of cytokines and immunosuppressive drugs on major histocompatibility complex class I/II expression by human cardiac myocytes in vitro. Human Immunology, 1991, 31, 123-133.	1.2	20
82	Interleukin-6 enhances the expression of tumor necrosis factor receptors on hepatoma cells and hepatocytes. Cytokine, 1991, 3, 149-154.	1.4	25
83	The Lack of Receptors for Atrial Natriuretic Peptides on Human Monocytes Prevents a Rise of cGMP and Induction of Tumor Necrosis Factor-α Synthesis. Immunobiology, 1991, 183, 94-101.	0.8	12
84	Malignant mesothelioma: the antiproliferative effect of cytokine combinations on three human mesothelioma cell lines. Cancer Letters, 1991, 58, 205-210.	3.2	21
85	The interferon family stimulates the secretions of prolactin and interleukin-6 by the pituitary gland in vitro. Journal of Endocrinological Investigation, 1991, 14, 457-461.	1.8	34
86	Tumor necrosis factor-induced interleukin-6 expression and cytotoxicity follow a common signal transduction pathway in L929 cells. Biochemical and Biophysical Research Communications, 1991, 178, 993-1001.	1.0	18
87	Tumor necrosis factor Characterization at the molecular, cellular and in vivo level. FEBS Letters, 1991, 285, 199-212.	1.3	626
88	A specific and reliable bioassay for the detection of femtomolar levels of human and murine tumor necrosis factors. Journal of Immunological Methods, 1991, 143, 251-261.	0.6	52
89	Effects of interleukin $1 \cdot \hat{l}^2$ (IL-1) and combination of IL-1 and tumor necrosis factor on tumor growth and protein metabolism. Journal of Nutritional Biochemistry, 1991, 2, 553-559.	1.9	3
90	Ability of cell-sized beads bearing tumor cell membrane proteins to stimulate LAK cells to secrete interferon- \hat{l}^3 and tumor necrosis factor- $\hat{l}\pm 1$. Cellular Immunology, 1991, 134, 96-110.	1.4	1
91	Synergistic cytotoxicity of human recombinant tumour necrosis factor \hat{l}_{\pm} combined with microtubule effectors. Journal of Cancer Research and Clinical Oncology, 1991, 117, 239-243.	1.2	3

#	Article	IF	CITATIONS
92	Regulation of cell movement: the motogenic cytokines. Biochimica Et Biophysica Acta: Reviews on Cancer, 1991, 1072, 81-102.	3.3	89
93	Expression and Secretion of Leukocyte Chemotactic Cytokines by Normal Human Melanocytes and Melanoma Cells. Journal of Investigative Dermatology, 1991, 97, 593-599.	0.3	80
94	Somatostatin analogue rc-160 inhibits the growth of transplanted colon cancer in rats. International Journal of Cancer, 1991, 47, 765-770.	2.3	32
95	Inhibition of protein synthesis enhances the lytic effects of tumor necrosis factor \hat{l}^{\pm} and interferon \hat{l}^{3} in cell lines derived from gynecological malignancies. Cancer Immunology, Immunotherapy, 1991, 33, 183-188.	2.0	9
96	In vivo effects of human recombinant tumor necrosis factor alone and in combination with other biological response modifiers on human digestive organ cancer xenografts transplanted in nude mice. Biotherapy (Dordrecht, Netherlands), 1991, 3, 337-344.	0.7	4
97	Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. Journal of Neurosurgery, 1991, 75, 922-929.	0.9	56
98	Upregulation of Interferon- \hat{l}^3 Binding by Tumor Necrosis Factor and Lymphotoxin: Disparate Potencies of the Cytokines and Modulation of Their Effects by Phorbol Ester. Journal of Interferon Research, 1991, 11, 61-67.	1,2	20
99	Tumor Necrosis Factor-α Inhibits 1,25-Dihydroxyvitamin D ₃ -Stimulated Bone Gla Protein Synthesis in Rat Osteosarcoma Cells (ROS 17/2.8) by a Pretranslational Mechanism*. Endocrinology, 1991, 128, 2577-2582.	1.4	62
100	Tumor Necrosis Factor-α Increases Release of Arachidonate and Prolactin from Rat Anterior Pituitary Cells. Endocrinology, 1991, 128, 2791-2798.	1.4	32
101	Tolerance to Endotoxin Prevents Mortality in Infected Thermal Injury: Association with Attenuated Cytokine Responses. Journal of Infectious Diseases, 1992, 165, 859-864.	1.9	54
102	The L929 cell bioassay for murine tumour necrosis factor is not influenced by other murine cytokines. Journal of Immunological Methods, 1992, 151, 313-315.	0.6	13
103	Immunotherapy of ovarian cancer. Gynecologic Oncology, 1992, 45, 129-135.	0.6	5
104	TNF-mediated IL6 gene expression and cytotoxicity are co-inducible in TNF-resistant L929 cells. FEBS Letters, 1992, 302, 235-238.	1.3	15
105	Extracorporeal Photochemotherapy Induces the Production of Tumor Necrosis Factor- $\hat{l}\pm$ by Monocytes: Implications for the Treatment of Cutaneous T-Cell Lymphoma and Systemic Sclerosis. Journal of Investigative Dermatology, 1992, 98, 686-692.	0.3	174
106	Coley's vaccine and TNF therapy. Nature, 1992, 358, 630-630.	13.7	7
107	Enhancing Effect of Pokeweed Mitogen on the Proliferation and the Cytotoxicity of Lymphokineâ€activated Killer Cells. Japanese Journal of Cancer Research, 1992, 83, 631-637.	1.7	10
108	Augmentation of the radiation-induced antiproliferative effect m combined use of a derivative of nitrosourea, ACNU, with recombinant human tumor necrosis factor. Immunopharmacology, 1992, 23, 199-204.	2.0	1
109	Synergistic effects of tumour necrosis factor-? and interferon-? on feline haemopoietic progenitors. Comparative Haematology International, 1992, 2, 79-83.	0.5	1

#	Article	IF	Citations
110	Tumour location influences local cytokine production and host metabolism. Surgical Oncology, 1992, 1, 65-71.	0.8	10
111	Cytochrome P-450 induction in human lung tumor-derived cell lines. Characterisation and effects of inflammatory mediators. FEBS Journal, 1992, 208, 521-529.	0.2	11
112	Growth arrest of the breast cancer cell line, T47D, by TNF $\hat{l}\pm$; cell cycle specificity and signal transduction. British Journal of Cancer, 1993, 67, 290-296.	2.9	31
113	Improving on the formula. Nature, 1993, 361, 206-207.	13.7	13
114	Human TNF mutants with selective activity on the p55 receptor. Nature, 1993, 361, 266-269.	13.7	177
115	Tumor necrosis factor activities and cancer therapy â€" A perspective. , 1993, 57, 79-128.		101
116	Interferon \hat{I}^3 and tumour necrosis factor \hat{I}^\pm induce a synergistic antiproliferative response in human Ewing's sarcoma cells in vitro. Journal of Cancer Research and Clinical Oncology, 1993, 119, 615-621.	1.2	39
117	Cell membrane permeabilization and cellular collapse, followed by loss of dehydrogenase activity: Early events in tumour necrosis factor-induced cytotoxicity. Cytokine, 1993, 5, 546-555.	1.4	97
118	Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study Journal of Clinical Oncology, 1993, 11, 2205-2210.	0.8	43
119	Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants EMBO Journal, 1994, 13, 843-850.	3.5	132
120	Growth Inhibition of Human Endothelial Cells by Human Recombinant Tumor Necrosis Factor Alpha and Interferon-Gamma. Tumori, 1994, 80, 301-305.	0.6	5
121	Mapping the lectin-like activity of tumor necrosis factor. Science, 1994, 263, 814-817.	6.0	212
122	Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA American Journal of Respiratory Cell and Molecular Biology, 1994, 11, 270-278.	1.4	31
123	Four epitopes on tumor necrosis factor-alpha defined by murine anti-tumor necrosis factor-alpha monoclonal antibodies. Immunology Letters, 1994, 41, 139-145.	1.1	4
124	Effect of interferon? and tumour necrosis factor? on sensitivity to cisplatin in ovarian carcinoma cell lines. Cancer Immunology, Immunotherapy, 1994, 39, 100-104.	2.0	9
125	Human tumor necrosis factor mutants with preferential binding to and activity on either the R55 or R75 receptor. FEBS Journal, 1994, 220, 771-779.	0.2	44
126	Generation and characterization of mouse microglial cell lines. Journal of Neuroimmunology, 1994, 52, 153-164.	1.1	35
127	pp $60\hat{l}^{1}/2$ -srckinase overexpression leads to cellular resistance to the antiproliferative effects of tumor necrosis factor. FEBS Letters, 1994, 345, 219-224.	1.3	11

#	Article	IF	CITATIONS
128	Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. FEBS Letters, 1994, 340, 9-16.	1.3	232
129	Influence of the postnatal administration of tumor necrosis factor plus interferon-α2b on the developments of ethyl-nitrosourea-induced brain tumors in rats. Neuroscience Letters, 1994, 174, 213-216.	1.0	4
130	Impairment of Pulmonary Macrphage Function with Total Parenteral Nutrition. Annals of Surgery, 1994, 219, 291-297.	2.1	51
131	Polar agents with differentiation inducing capacity potentiate tumor necrosis factor-mediated cytotoxicity in human myeloid cell lines. Journal of Leukocyte Biology, 1995, 57, 141-151.	1.5	16
132	Rapid induction of tumor necrosis factor alpha in the cerebrospinal fluid after intracerebroventricular injection of lipopolysaccharide revealed by a sensitive capture immuno-PCR assay Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 272-275.	3.3	73
133	Expression of type a and b tumor necrosis factor (TNF) receptors on melanoma cells can be regulated by dbc-AMP and IFN- \hat{l}^3 . International Journal of Cancer, 1995, 62, 76-83.	2.3	15
134	Antiâ€ŧumor activity of tumor necrosis factor in combination with interferonâ€Ĵ³ is not affected by prior tolerization. International Journal of Cancer, 1995, 63, 846-854.	2.3	11
135	Potentiation of antitumor effects of tumor necrosis factor $\hat{l}\pm$ and interferon \hat{l}^3 by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice. Cancer Immunology, Immunotherapy, 1995, 40, 315-321.	2.0	35
136	Regression of Human Breast Cancer Xenografts in Response to Intralesional Treatment with Interferons $\hat{l}\pm$ and \hat{l}^3 Potentiated by Tumor Necrosis Factor. Journal of Interferon and Cytokine Research, 1995, 15, 839-848.	0.5	8
137	Tumor necrosis factor-α and X-linked adrenoleukodystrophy. Journal of Neuroimmunology, 1995, 61, 161-169.	1.1	48
138	Suppression of antiproliferative effects of tumor necrosis factor by transfection of cells with human platelet-derived growth factor B/c-sis gene. FEBS Letters, 1995, 357, 1-6.	1,3	7
139	Extremely high production of thymidine by TNF-susceptible L929 cells. Cancer Letters, 1995, 89, 169-176.	3.2	2
140	Tumour necrosis factor and interferon are selectively cytostatic in vitro for hormone-dependent and hormone-independent human breast cancer cells. European Journal of Cancer, 1996, 32, 2312-2318.	1.3	21
141	Recombinant human tumour necrosis factor-α suppresses synthesis, activity and secretion of lipoprotein lipase in cultures of a human osteosarcoma cell line. Biochemical Journal, 1996, 316, 813-817.	1.7	11
142	Bleb formation and F-actin distribution during mitosis and tumor necrosis factor-induced apoptosis. Microscopy Research and Technique, 1996, 34, 272-280.	1.2	89
143	Tumour necrosis factor-alpha (TNF-α): The good, the bad and potentially very effective. Immunology and Cell Biology, 1996, 74, 434-443.	1.0	98
144	Inhibitory Effects of Interleukin-4 on Human Renal Cell Carcinoma Cells In Vitro: In Combination with Interferon-?, Tumor Necrosis Factor-? or Interleukin-2. International Journal of Urology, 1996, 3, 196-201.	0.5	6
145	Interferon-Î ³ Modulates a p53-independent Apoptotic Pathway and Apoptosis-related Gene Expression. Journal of Biological Chemistry, 1997, 272, 16351-16357.	1.6	245

#	Article	IF	CITATIONS
146	Tumour eradication with high-dose idarubicin-anti-Ly-2.1 with murine tumour necrosis factor- \hat{l}_{\pm} in mice. Immunology and Cell Biology, 1997, 75, 253-258.	1.0	2
148	High-level constitutive expression of alpha 1-acid glycoprotein and lack of protection against tumor necrosis factor-induced lethal shock in transgenic mice. Transgenic Research, 1998, 7, 429-435.	1.3	15
149	Inhibition of establishment and growth of mouse liver metastases after treatment with interferon gamma and \hat{l}^2 -1,3-D-glucan. Hepatology, 1998, 27, 1241-1248.	3.6	22
150	Cell surface and nuclear changes during TNF-α-induced apoptosis in WEHI 164 murine fibrosarcoma cells. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1998, 433, 75-83.	1.4	40
151	Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cellular and Molecular Life Sciences, 1998, 54, 1291-1298.	2.4	49
152	Clinical Management and Current Research in Isolated Limb Perfusion for Sarcoma and Melanoma. Oncology, 1998, 55, 89-102.	0.9	19
153	Tumour Necrosis Factor: Strategies for Improving the Therapeutic Index. Journal of Drug Targeting, 1998, 5, 403-413.	2.1	13
154	Tumor Necrosis Factor and Lymphotoxin. , 1998, , 335-360.		45
155	Interferon- \hat{l}^3 rescues TNF- $\hat{l}\pm$ -induced apoptosis mediated by up-regulation of TNFR2 on EoL-1 cells. Experimental Hematology, 1999, 27, 512-519.	0.2	25
156	Effect of Calcium Channel Blockers, Nifedipine and Benidipine, on Death of Cultured Mouse Mesangi al Cells. Kidney and Blood Pressure Research, 2000, 23, 126-132.	0.9	4
157	CD4 + T Cell–Mediated Tumor Rejection Involves Inhibition of Angiogenesis that Is Dependent on IFNγ Receptor Expression by Nonhematopoietic Cells. Immunity, 2000, 12, 677-686.	6.6	461
158	Lectin-deficient TNF mutants display comparable anti-tumour but reduced pro-metastatic potential as compared to the wild-type molecule. International Journal of Cancer, 2001, 91, 543-549.	2.3	8
159	Regulation of Tumor Growth by IFN-Γ in Cancer Immunotherapy. Immunologic Research, 2001, 24, 201-210.	1.3	83
160	Translation Inhibition in Apoptosis. Journal of Biological Chemistry, 2001, 276, 41620-41628.	1.6	159
161	IFN-γ/TNF-α Synergism as the Final Effector in Autoimmune Diabetes: A Key Role for STAT1/IFN Regulatory Factor-1 Pathway in Pancreatic β Cell Death. Journal of Immunology, 2001, 166, 4481-4489.	0.4	201
162	Signaling to gene activation and cell death by tumor necrosis factor receptors and fas. International Review of Cytology, 2002, 214, 225-272.	6.2	40
163	Extracorporeal photopheresis reduces the number of mononuclear cells that produce pro-inflammatory cytokines, when tested ex-vivo. Journal of Clinical Apheresis, 2002, 17, 177-182.	0.7	19
164	Interferon regulatory factor-1 mediates interferon-?-induced apoptosis in ovarian carcinoma cells. Journal of Cellular Biochemistry, 2002, 85, 369-380.	1.2	69

#	Article	IF	Citations
165	Death and anti-death: tumour resistance to apoptosis. Nature Reviews Cancer, 2002, 2, 277-288.	12.8	1,756
166	CD4 + T CELL MATTERS IN TUMOR IMMUNITY. International Reviews of Immunology, 2003, 22, 113-140.	1.5	34
167	The cytokinesAn overview., 2003,, 3-18.		28
168	Chimeric TNT-3/Human \hat{l}^2 -Glucuronidase Fusion Proteins for Antibody-Directed Enzyme Prodrug Therapy (ADEPT). Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 339-353.	0.7	27
169	Crucial Role for Interferon \hat{I}^3 in the Synergism between Tumor Vasculature-Targeted Tumor Necrosis Factor \hat{I}^{\pm} (NGR-TNF) and Doxorubicin. Cancer Research, 2004, 64, 7150-7155.	0.4	66
170	TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor α, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up. Annals of Surgical Oncology, 2005, 12, 825-830.	0.7	67
171	CD4 T cells in tumor immunity. Seminars in Immunopathology, 2005, 27, 37-48.	4.0	82
172	Targeted Delivery of IFN \hat{I}^3 to Tumor Vessels Uncouples Antitumor from Counterregulatory Mechanisms. Cancer Research, 2005, 65, 2906-2913.	0.4	87
173	A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo. Cytotherapy, 2006, 8, 415-423.	0.3	15
174	The Response of Human Epithelial Cells to TNF Involves an Inducible Autocrine Cascade. Cell, 2006, 124, 1225-1239.	13.5	188
175	Adenoviral vector saturates Akt pro-survival signaling and blocks insulin-mediated rescue of tumor-necrosis-factor-induced apoptosis. Journal of Cell Science, 2006, 119, 3788-3798.	1.2	21
176	Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer, 2007, 7, 158.	1.1	44
177	Targeted delivery of TNF using NGR-TNF in combination with chemotherapy as an effective and tolerable strategy in a hepatocarcinoma patient. Memo - Magazine of European Medical Oncology, 2008, 1, 43-46.	0.3	0
178	Prolonged exposure to IL-1β and IFNγ induces necrosis of L929 tumor cells via a p38MAPK/NF-κB/NO-dependent mechanism. Oncogene, 2008, 27, 3780-3788.	2.6	20
179	Treatment of murine macrophages with murine interferon-gamma and tumour necrosis factor-alpha enhances uptake and intracellular killing of Pseudomonas aeruginosa. Clinical and Experimental Immunology, 2008, 93, 165-171.	1.1	23
180	Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN- \hat{l}^3) and tumour necrosis factor-alpha (TNF- \hat{l}^\pm) on human renal cell carcinoma. Clinical and Experimental Immunology, 2008, 96, 476-483.	1.1	18
181	Induction <i>in vitro</i> of 72-kD heat shock protein in a continuous culture of rat thyroid cells, FRTL5. Clinical and Experimental Immunology, 2008, 98, 234-239.	1.1	3
182	Dynamic localization of tripartite motif-containing 22 in nuclear and nucleolar bodies. Experimental Cell Research, 2009, 315, 1521-1532.	1.2	20

#	Article	IF	CITATIONS
183	NKG2D-retinoic acid early inducible-1 recognition between natural killer cells and kupffer cells in a novel murine natural killer cell-dependent fulminant hepatitis. Hepatology, 2009, 49, 940-949.	3.6	88
184	Tumour necrosis factor and cancer. Nature Reviews Cancer, 2009, 9, 361-371.	12.8	1,514
185	Effect of tumour necrosis factorâ€l± and irradiation alone or in combination on the viability of hepatocellular and biliary adenocarcinoma cell lines <i>in vitro</i> . Liver International, 2009, 29, 910-921.	1.9	1
186	A novel Salmonella Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer. Vaccine, 2011, 29, 728-736.	1.7	44
187	LiCl induces TNF- $\hat{l}\pm$ and FasL production, thereby stimulating apoptosis in cancer cells. Cell Communication and Signaling, 2011, 9, 15.	2.7	25
188	A model for cancer-suppressive inflammation. Oncolmmunology, 2012, 1, 1146-1155.	2.1	64
189	TNF-α Induces Epithelial–Mesenchymal Transition of Renal Cell Carcinoma Cells via a GSK3β-Dependent Mechanism. Molecular Cancer Research, 2012, 10, 1109-1119.	1.5	102
190	Tumor Necrosis Factor-alpha Potentiates the Cytotoxicity of Amiodarone in Hepa1c1c7 Cells: Roles of Caspase Activation and Oxidative Stress. Toxicological Sciences, 2013, 131, 164-178.	1.4	16
191	TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants $\hat{a} \in \text{``past,}$ present and future. Cytokine and Growth Factor Reviews, 2014, 25, 453-472.	3.2	643
192	cFLIP is critical for oligodendrocyte protection from inflammation. Cell Death and Differentiation, 2015, 22, 1489-1501.	5.0	11
193	Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics. Journal of Immunology, 2015, 194, 2049-2056.	0.4	119
194	Prolonged Tumor Necrosis Factor α Primes Fibroblastâ€like Synoviocytes in a Geneâ€Specific Manner by Altering Chromatin. Arthritis and Rheumatology, 2015, 67, 86-95.	2.9	60
195	Vascular-targeted TNF $\hat{l}\pm$ and IFN \hat{l}^3 inhibits orthotopic colorectal tumor growth. Journal of Translational Medicine, 2016, 14, 187.	1.8	17
196	Functional Heterogeneity of CD4+ Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC. Frontiers in Immunology, 2018, 9, 2654.	2.2	85
197	Autophagy genes in myeloid cells counteract IFNγ-induced TNF-mediated cell death and fatal TNF-induced shock. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16497-16506.	3.3	35
198	Dynamic changes in chemosensitivity immune predictors in patients with hypopharyngeal cancer treated with induction chemotherapy. Head and Neck, 2019, 41, 2380-2388.	0.9	2
199	Telomerase and CD4 T Cell Immunity in Cancer. Cancers, 2020, 12, 1687.	1.7	20
200	Structure – Functton Relationship of Tumour Necrosis Factor and its Mechanism of Action. Novartis Foundation Symposium, 1987, 131, 109-123.	1.2	6

#	Article	IF	CITATIONS
201	Animal Model Systems to Evaluate the Antitumor Activity of Interferons. , 1988, , 307-317.		1
202	Synergistic Actions of Interferons and Tumor Necrosis Factor. , 1988, , 353-363.		1
203	Immunological Aspects of Tumor-Macrophage Interactions. Advances in Experimental Medicine and Biology, 1988, 233, 49-59.	0.8	5
204	Tumour Necrosis Factor and Interleukin-6: Structure and Mechanism of Action of the Molecular, Cellular and in Vivo Level., 1989,, 229-240.		2
205	In Vitro Sensitivity of Three Human Renal Tumor Xenografts Towards Tumor Necrosis Factor and Alpha and Gamma Interferon., 1989,, 30-38.		2
207	Cytokine therapy. Cancer Biology and Medicine, 1990, , 127-159.	0.1	3
210	Different and synergistic actions of human tumor necrosis factor and interferon-gamma in damage of liposome membranes Journal of Biological Chemistry, 1987, 262, 4597-4601.	1.6	25
211	Tumor necrosis factor induces synthesis of two proteins in human fibroblasts Journal of Biological Chemistry, 1986, 261, 9565-9567.	1.6	58
212	Tumor necrosis factor up-regulates gamma-interferon binding in a human carcinoma cell line Journal of Biological Chemistry, 1990, 265, 10466-10472.	1.6	45
213	The antimitogenic action of tumor necrosis factor is associated with increased AP-1/c-jun proto-oncogene transcription. Journal of Biological Chemistry, 1989, 264, 16905-16909.	1.6	50
214	In vitro and in vivo induction of tumor necrosis factor alpha by Borrelia burgdorferi. Infection and Immunity, 1992, 60, 1109-1113.	1.0	95
215	Generation of a mouse tumor necrosis factor mutant with antiperitonitis and desensitization activities comparable to those of the wild type but with reduced systemic toxicity. Infection and Immunity, 1997, 65, 2006-2010.	1.0	26
216	A protein serologically and functionally related to the group C E3 14,700-kilodalton protein is found in multiple adenovirus serotypes. Journal of Virology, 1990, 64, 1250-1255.	1.5	49
217	Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis. Journal of Virology, 1991, 65, 2629-2639.	1.5	84
218	Characterization of mutants within the gene for the adenovirus E3 14.7-kilodalton protein which prevents cytolysis by tumor necrosis factor. Journal of Virology, 1993, 67, 2159-2167.	1.5	61
219	The activity of cytosolic phospholipase A2 is required for the lysis of adenovirus-infected cells by tumor necrosis factor. Journal of Virology, 1996, 70, 8502-8507.	1.5	54
220	Tumor necrosis factor can induce fever in rats without activating protein breakdown in muscle or lipolysis in adipose tissue Journal of Clinical Investigation, 1988, 81, 1384-1389.	3.9	100
221	Cachectin/tumor necrosis factor-alpha formation in human decidua. Potential role of cytokines in infection-induced preterm labor Journal of Clinical Investigation, 1989, 83, 430-436.	3.9	278

#	ARTICLE	IF	Citations
223	Early responses to tumor necrosis factor of human promyelocytic leukemia cell lines sensitive and resistant to the factor Cell Structure and Function, 1988, 13, 241-248.	0.5	1
224	Tumor Mouse Model Confirms MAGE-A3 Cancer Immunotherapeutic As an Efficient Inducer of Long-Lasting Anti-Tumoral Responses. PLoS ONE, 2014, 9, e94883.	1.1	26
225	The Roles of CD4 ⁺ T Cells in Tumor Immunity. ISRN Immunology, 2011, 2011, 1-6.	0.7	33
226	Cytokine Synergism in Apoptosis: Its Role in Diabetes and Cancer. BMB Reports, 2002, 35, 54-60.	1.1	6
227	Effects of Tumour Necrosis Factor on Human Tumour Xenografts in Nude Mice. Novartis Foundation Symposium, 1987, 131, 154-169.	1.2	1
228	Mechanisms of Anticancer Action of Interferons on Human Tumour Xenografts in Nude Mice. , 1987, , 293-300.		0
229	Modulation of Class I and Class II Major Histocompatibility Complex Antigens in Gliomas. , 1987 , , $107-113$.		0
230	The Effect of Human and Murine Interferons on Human Tumour Xenografts. , 1988, , 91-94.		0
231	Interaction of Monoclonal Antibodies with Biological Response Modifiers and Cytostatics. , 1989, , 56-70.		1
232	Synergism of Lymphotoxin and Interferon- \hat{l}^3 in the Growth Inhibition of Breast Cancer Cell Line MCF-7. , 1990, , 205-210.		0
233	Wechselwirkungen zwischen Interferonen und anderen Zytokinen. , 1990, , 406-419.		0
234	Therapy of the plasma cell tumors. , 1991, , 305-349.		0
235	Interferon and Tumor Necrosis Factor in Renal Cell Carcinoma Model Systems., 1991,, 47-55.		0
236	Tumor Necrosis Factor-Induced Gene Expression and Cytotoxicity Share a Signal Transduction Pathway., 1991,, 471-475.		0
237	Tumor Necrosis Factor: Mechanism of Action and its Potential for Anticancer Therapy., 1992,, 119-125.		0
238	Treatment with Human Recombinant Tumor Necrosis Factor-α of Patients with Acute Myeloid Leukemia and Chronic Myeloid Leukemia in its Accelerated or Blastic Phase. , 1992, , 693-706.		1
239	Growth Factors., 1992,, 57-121.		1
240	Lymphokines and Cytokines. , 1998, , 211-265.		2

#	ARTICLE	IF	CITATIONS
241	Resistance of Spontaneously Transformed Syrian Hamster Embryo Cells and Their Malignant Variants to Cytotoxic Activity of Recombinant Tumor Necrosis Factor-alpha. Cancer Detection and Prevention, 1998, 22, 176-184.	2.1	0
242	Unleashing TNF cytotoxicity to enhance cancer immunotherapy. Trends in Immunology, 2021, 42, 1128-1142.	2.9	28
248	Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO Journal, 1994, 13, 843-50.	3. 5	41
249	Synergistic effects of recombinant tumour necrosis factor and interferon-gamma on rat thyroid cell growth and la antigen expression. Immunology, 1988, 63, 285-9.	2.0	38
250	Apoptosis induced by tumor necrosis factor-alpha in rat hepatocyte cell lines expressing hepatitis B virus. American Journal of Pathology, 1996, 148, 801-14.	1.9	24
251	Modulation of fibronectin production in normal human melanocytes and malignant melanoma cells by interferon-gamma and tumor necrosis factor-alpha. American Journal of Pathology, 1989, 134, 827-36.	1.9	15
252	Induction of inflammatory cell infiltration and necrosis in normal mouse skin by the combined treatment of tumor necrosis factor and lithium chloride. American Journal of Pathology, 1991, 138, 727-39.	1.9	9
253	Toxicity of tumor necrosis factor is synergistic with gamma-interferon and can be reduced with cyclooxygenase inhibitors. American Journal of Pathology, 1987, 128, 410-25.	1.9	79
254	Combinatory lung tumor inhibition by myo-inositol and iloprost/rapamycin: association with immunomodulation. Carcinogenesis, 2022, 43, 547-556.	1.3	3
257	Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest Journal of Immunology, 1994, 153, 1778-1788.	0.4	392
258	Involvement of IFN-gamma in Bacillus Calmette-Guérin-induced but not in tumor-induced sensitization to TNF-induced lethality Journal of Immunology, 1995, 154, 2753-2763.	0.4	10
259	Sustained Phosphorylation of Cytosolic Phospholipase A2 Accompanies Cycloheximide- and Adenovirus-Induced Susceptibility to TNF. Journal of Immunology, 1998, 161, 1525-1532.	0.4	14